Idera Pharmaceuticals, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research.
The company stated in the following report that they conduct pre-clinical trials of their drugs on animals.
“Entered into collaborations with leading GvHD investigators at Ohio State University, Washington University in St. Louis, and the University of Minnesota to carry out preclinical evaluations of TLR antagonist candidates in both acute and chronic GvHD animal models, in concert with Idera’s plan to initiate clinical development of IMO-8400 for GvHD by year-end.” Read the following article
Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company, which is engaged in discovery, development and commercialization of novel oligonucleotide therapeutics for oncology and rare diseases. The company uses two distinct proprietary drug discovery technology platforms to design and develop drug candidates: Toll-like receptor targeting technology and third-generation antisense technology. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Cambridge, MA. [Source: MarketWatch]
Company Website: http://www.iderapharma.com